Renal Cell Carcinoma Clinical Trials

A listing of Renal Cell Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 257 clinical trials
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.

lenvatinib
carcinoma
pembrolizumab
cancer
karnofsky performance status
  • 0 views
  • 31 Jul, 2021
  • 55 locations
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.

carcinoma
karnofsky performance status
  • 26 views
  • 19 May, 2021
  • 7 locations
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

molecule multi-kinase inhibitor of VEGFR, PDGFR and RAF with demonstrated activity in the treatment of renal cell cancer (9). Preclinical studies suggest that the combination of Sorafenib with

ewing's sarcoma
anthracyclines
monoclonal antibodies
neutrophil count
small molecule
  • 13 views
  • 07 Nov, 2020
  • 1 location
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

renal cell carcinoma (RCC).

carcinoma
growth factor
tyrosine
metastasis
metastatic renal cell carcinoma
  • 27 views
  • 21 May, 2021
  • 45 locations
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902) or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib Versus Pembrolizumab and Lenvatinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to

lenvatinib
carcinoma
pembrolizumab
systemic therapy
clear cell renal cell carcinoma
  • 0 views
  • 01 Aug, 2021
  • 81 locations
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is …

solid tumour
carcinoma
advanced renal cell carcinoma
growth factor
everolimus
  • 168 views
  • 31 Jul, 2021
  • 182 locations
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The

carcinoma
advanced renal cell carcinoma
growth factor
tyrosine
measurable disease
  • 0 views
  • 30 Jul, 2021
  • 45 locations
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior

lenvatinib
carcinoma
advanced renal cell carcinoma
cabozantinib
measurable disease
  • 0 views
  • 29 Jul, 2021
  • 54 locations
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy

lenvatinib
carcinoma
pembrolizumab
systemic therapy
major surgery
  • 0 views
  • 13 Jul, 2021
  • 22 locations
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy

lenvatinib
carcinoma
monoclonal antibodies
growth factor
pembrolizumab
  • 0 views
  • 13 Jul, 2021
  • 23 locations